Which funds bought or sold CRL in Q3 2026?
Charles Riv Labs Intl Inc. 3 funds bought, 6 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$561M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Fidelity+$511M
- Arrowstreet+$177M
- BridgewaterNEW+$21M
- Invesco−$334M
- Wellington−$314M
- Oakmark−$245M
- Citadel−$204M
- Ameriprise−$133M
- AllianceBernstein−$67M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (3)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Fidelity Asset manager | Added+40.9% | +$511M | $1.8B |
| Arrowstreet Quant & multi-strategy | Added+214.8% | +$177M | $259M |
| Bridgewater Hedge fund | New | +$21M | $21M |
Sold (6)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Invesco Asset manager | Trimmed-37.9% | −$334M | $547M |
| Wellington Asset manager | Trimmed-82.5% | −$314M | $67M |
| Oakmark Value investor | Trimmed-37.1% | −$245M | $416M |
| Citadel Quant & multi-strategy | Trimmed-57.9% | −$204M | $148M |
| Ameriprise Asset manager | Trimmed-51.1% | −$133M | $127M |
| AllianceBernstein Asset manager | Trimmed-60.9% | −$67M | $43M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.